ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

FDA Advisory Committee To Consider NDAs On Novantrone, HD MTX

November 27, 1987

Amgen Claimed QOL Benefit Despite FDA Label Change.

May 18, 2007

Yarbro-Chabner Debate Continues

April 29, 1983

NCI Cooperative Group, Cancer Center Trials Listed

May 30, 2008

DeVita Losing Patience, Responds To Powers Letter

May 6, 1983

Commission Seeks Comparative Data on Cervical Cancer

August 16, 1991